Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

A Massachusetts man who, along with his girlfriend, defrauded Takeda Pharmaceutical Co. of $2.3 million and used the money to ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

A Brockton man was sentenced for defrauding a pharmaceutical company out of $2.3 million and spending the proceeds on a ...

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

In honor of Rare Disease Day, the Celtics are teaming with Takeda Pharmaceuticals to raise awareness and support for the rare disease community.